Department of Cardiology, Daqing Fifth Hospital, Daqing, China.
Department of Cardiology, Daqing Oil Field General Hospital, Daqing, China.
J Clin Lab Anal. 2021 Apr;35(4):e23593. doi: 10.1002/jcla.23593. Epub 2021 Mar 4.
This study aimed to explore the correlation of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA MALAT1) with microRNA (miR)-125b and further investigated their associations with disease risk, severity, and prognosis of coronary heart disease (CHD).
Totally, 230 patients who underwent diagnostic coronary angiography were recruited; meanwhile, 140 of them were diagnosed as CHD and the remaining 90 non-CHD patients served as controls. Plasma sample was collected from each participant for lncRNA MALAT1 and miR-125b mRNA expression detection by reverse transcription-quantitative polymerase chain reaction. The extent of coronary stenosis was evaluated by the Gensini score, and major adverse cardiovascular event (MACE) occurrence during the follow-up was documented in CHD patients.
Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 relative expression was increased, but miR-125b relative expression was decreased in CHD patients compared with controls. ROC curve exhibited that lncRNA MALAT1 and miR-125b were of good value in differentiating CHD patients from controls, and further logistic regression analysis verified their independent correlation with CHD risk. Furthermore, lncRNA MALAT1 presented a closely negative correlation with miR-125b in CHD patients, while it presented a weakly negative association with miR-125b in controls. In CHD patients, lncRNA MALAT1 was positively correlated with Gensini score, total cholesterol, low-density lipoprotein cholesterol, C-reactive protein, tumor necrosis factor α, interleukin (IL)-1β, IL-6, IL-17, and accumulating MACE occurrence; reversely, miR-125b presented a opposite trend.
Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 might be associated with increased CHD risk, severity, and accumulating MACE incidence via negative interaction with miR-125b, suggesting their possible clinical application as biomarkers in the CHD screening and surveillance.
本研究旨在探讨长链非编码 RNA 转移相关肺腺癌转录本 1（lncRNA MALAT1）与 microRNA（miR）-125b 的相关性，并进一步研究它们与冠心病（CHD）发病风险、严重程度和预后的关系。
共招募 230 例接受诊断性冠状动脉造影的患者；其中 140 例诊断为 CHD，其余 90 例非 CHD 患者作为对照。收集每位参与者的血浆样本，通过逆转录定量聚合酶链反应检测 lncRNA MALAT1 和 miR-125b mRNA 的表达。通过 Gensini 评分评估冠状动脉狭窄程度，并记录 CHD 患者随访期间的主要不良心血管事件（MACE）发生情况。
与对照组相比，CHD 患者 lncRNA MALAT1 相对表达增加，而 miR-125b 相对表达降低。ROC 曲线显示，lncRNA MALAT1 和 miR-125b 对区分 CHD 患者和对照组具有良好的价值，进一步的逻辑回归分析证实了它们与 CHD 风险的独立相关性。此外，在 CHD 患者中，lncRNA MALAT1 与 miR-125b 呈密切负相关，而在对照组中与 miR-125b 呈弱负相关。在 CHD 患者中，lncRNA MALAT1 与 Gensini 评分、总胆固醇、低密度脂蛋白胆固醇、C 反应蛋白、肿瘤坏死因子-α、白细胞介素（IL）-1β、IL-6、IL-17 呈正相关，与累积 MACE 发生率呈正相关；相反，miR-125b 呈相反趋势。
lncRNA MALAT1 可能通过与 miR-125b 的负相互作用与 CHD 风险增加、严重程度增加和累积 MACE 发生率相关，提示其作为 CHD 筛查和监测的生物标志物具有潜在的临床应用价值。
